Sheffield Medical Technologies and Johns Hopkins Collaborate on Clinical Development of AIDS Therapeutic; Planning Underway for RBC-CD4 Phase IIA Clinical Trial

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Sheffield Medical Technologies and Johns Hopkins Collaborate on Clinical Development of AIDS Therapeutic; Planning Underway for RBC-CD4 Phase IIA Clinical Trial

Business Wire (10/25/93)

Houston--Sheffield Medical Technologies Inc. announced that Johns Hopkins University will conduct a double-blinded, Phase II clinical trial of Sheffield's red blood cell(RBC)-CD4 Complex in 12 HIV-infected patients. The study is designed to evaluate the antiviral activity of the RBC-CD4 Complex on viral load and to determine the safety and tolerability of recombinant full-length CD4 electroinserted into red blood cells. "Given the lack of toxicity demonstrated in Phase I and the positive results of in vitro patient isolate studies, we are optimistic that the RBC-CD4 electroinsertion technology may offer a new mode of therapy for physicians to provide their patients," said Dr. Claude Nicolau, co-inventor of the technology, visiting professor of medicine at Harvard Medical School, and director of the Blood Research and Development Laboratory at the Center for Blood Research Laboratories Inc.

931028
AD931956

Copyright © 1993 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.